---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-030400"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:25:04.539742+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics reports Q1 net loss $3.4M; submits GTx-104 NDA to FDA

## Summary
- Net loss $3.4M ($0.21/sh) vs $2.6M ($0.24/sh) in prior-year quarter; R&D down $1.8M to $0.9M.
- Submitted NDA to FDA for GTx-104 (IV nimodipine) for aneurysmal subarachnoid hemorrhage; based on positive STRIVE-ON Phase 3 trial.
- STRIVE-ON met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine; 54% patients had ≥95% relative dose intensity.
- Cash and equivalents $20.0M; potential warrant exercises of $22.6M ($7.6M + $15.0M) could extend runway into Q2 2027.
- Deprioritized GTx-102 and GTx-101 to focus on GTx-104; may license or sell those assets.

## SEC filing metadata
- accession: 0001140361-25-030400
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/0001140361-25-030400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/ef20053073_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-030400
- JSON: https://secwatch.observer/filing/0001140361-25-030400.json
- Plain text: https://secwatch.observer/filing/0001140361-25-030400.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.